Bringing the symptoms of inflammatory bowel disease under control can be onerous for patients and their families. Maintenance infusions of biologics such as infliximab (Remicade, Janssen) and vedolizumab (Entyvio, Millennium) in hospital infusion centers require pediatric patients to miss school and parents or adult patients to miss work on a regular basis.
The challenges are even greater for individuals who travel long distances to receive hospital infusions or for families who are